EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective

Bob G Schultz, Camille N Kotton, Ginita Jutlla, Riccardo Ressa, Tam de Lacey, Emtiyaz Chowdhury, Tien Bo, Elisabetta Fenu, Daniele K Gelone, Jean-Etienne Poirrier, Stacey L Amorosi

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29609 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Bob G Schultz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Cytomegalovirus Infections, Antiviral Agents, Ribonucleosides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the cost‐effectiveness of maribavir versus investigator‐assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for post‐transplant refractory cytomegalovirus (CMV) infection with or without resistance. A two‐stage Markov model was designed using data from the SOLSTICE trial (NCT02931539), real‐world multinational observational studies, and published literature. Stage 1 (0–78 weeks) comprised clinically significant CMV (csCMV), non‐clinically significant CMV (n‐csCMV), and dead states; stage 2 (78 weeks–lifetime) comprised alive and dead states. Total costs (2022 USD) and quality‐adjusted life years (QALYs) were estimated for the maribavir and IAT cohorts. An incremental cost‐effectiveness ratio was calculated to determine cost‐effectiveness against a willingness‐to‐pay threshold of $100 000/QALY. Compared with IAT, maribavir had lower costs ($139 751 vs $147 949) and greater QALYs (6.04 vs 5.83), making it cost‐saving and more cost‐effective. Maribavir had higher acquisition costs compared with IAT ($80 531 vs $65 285), but lower costs associated with administration/monitoring ($16 493 vs $27 563), adverse events (AEs) ($11 055 vs $16 114), hospitalization ($27 157 vs $33 905), and graft loss ($4516 vs $5081), thus making treatment with maribavir cost‐saving. Maribavir‐treated patients spent more time without CMV compared with IAT‐treated patients (0.85 years vs 0.68 years), leading to lower retreatment costs for maribavir (cost savings: −$42 970.80). Compared with IAT, maribavir was more cost‐effective for transplant recipients with refractory CMV, owing to better clinical efficacy and avoidance of high costs associated with administration, monitoring, AEs, and hospitalizations. These results can inform healthcare decision‐makers on the most effective use of their resources for post‐transplant refractory CMV treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisCytomegalovirus InfectionsAntiviral AgentsRibonucleosidesBenzimidazolesQuality-Adjusted Life YearsHumansUnited StatesCytomegalovirusDrug Resistance, ViralMaleFemaleMiddle AgedAdultGenotypeTransplant RecipientsDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

cost‐effectivenesscytomegalovirusmaribavirquality‐adjusted life years

Substanzen

maribavirAntiviral AgentsRibonucleosidesBenzimidazolesDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA.
  • Infectious Diseases Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Parexel, Health Economics and Outcomes Research Modeling, London, UK.
  • Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
  • Takeda Global Health Economics, Zurich, Switzerland.
  • Parexel, Health Economics and Outcomes Research Modeling, Wavre, Belgium.

Förderung

  • Takeda Pharmaceuticals U.S.A., Inc.

Zitieren

APA

Schultz, B. G., Kotton, C. N., Jutlla, G., Ressa, R., de Lacey, T., Chowdhury, E., Bo, T., Fenu, E., Gelone, D. K., Poirrier, J. E., & Amorosi, S. L. (2024). Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective. Journal of Medical Virology. https://doi.org/10.1002/jmv.29609

Vancouver

Schultz BG, Kotton CN, Jutlla G, Ressa R, de Lacey T, Chowdhury E, et al. Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective. Journal of Medical Virology. 2024. doi:10.1002/jmv.29609

BibTeX
@article{Schultz2024,
  author = {Schultz, Bob G and Kotton, Camille N and Jutlla, Ginita and Ressa, Riccardo and de Lacey, Tam and Chowdhury, Emtiyaz and Bo, Tien and Fenu, Elisabetta and Gelone, Daniele K and Poirrier, Jean-Etienne and Amorosi, Stacey L},
  title = {Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29609}
}
Kostenlos starten →